Top Markets
Coin of the day
TCR2 Therapeutics Inc. TCR2 Therapeutics Inc.

TCR2 Therapeutics Inc.

TCRR
Rangering i aksjer #27037
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on... TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on developing cutting-edge T cell receptor (TCR) therapies for cancer patients. The company's lead investigational treatment, gavo-cel, is a unique mono TCR Fusion Construct T cell (TRuC-T cell) designed to target mesothelin-positive solid tumors. This therapy is currently being evaluated in Phase I/II clinical trials for non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Furthermore, TCR2 Therapeutics has concluded preclinical development for TC-510, another TRuC-T cell specifically engineered to target mesothelin on solid tumors. They are also advancing TC-520, a CD70-targeting TRuC-T cell designed with fratricide resistance for treating renal cell carcinoma. Founded in 2015, the company, formerly known as TCR2, Inc. until its name change in November 2016, is headquartered in Cambridge, Massachusetts.
Aksjekurs
$1.48
Sist synkronisert: 2023-05-31
Markedsverdi
$35.54M
Endring (1 dag)
-5.73%
Endring (1 år)
0.00%
Land
US
Handel TCR2 Therapeutics Inc. (TCRR)

Kategori

Antall utestående aksjer for TCR2 Therapeutics Inc. (TCRR)
Antall utestående aksjer per August 2026: 0
Ifølge TCR2 Therapeutics Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 0. Ved slutten av August 2026 hadde selskapet 0 utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for TCR2 Therapeutics Inc. (TCRR) fra 2026 til 2026
Utestående aksjer ved utgangen av hvert år
År Utestående aksjer Endre
Ikke nok data for de angitte datoene.
Utestående aksjer for lignende selskaper eller konkurrenter
Selskap Utestående aksjer Forskjell Land
253.90M -
US
62.19M -
NL
483.58M -
AU
396.00M -
US
- -
CH